TITAN trial; shifting focus from hormone-refractory to hormone-sensitive prostate cancer

• Published in: Indian journal of urology Vol. 36; no. 2; pp. 144 - 145
• Main Author: Kumar, Gautam
• Format: Journal Article
• Language: English
• Published: Vellore Wolters Kluwer India Pvt. Ltd 01.04.2020; Medknow Publications & Media Pvt. Ltd; Wolters Kluwer - Medknow; Wolters Kluwer Medknow Publications
• Subjects: Androgens; Chemotherapy; Metastasis; Prostate cancer; Standard of care; Uroscan

[1] It included CSPC patients with distant metastatic disease measured by ≥1 lesion on bone scan, with or without visceral/lymph node involvement and ECOG performance status of 0–1. CHAARTED/STAMPEDE (arm C/E), GETUG-AFU15, and subsequent meta-analysis established ADT + docetaxel as a standard of ca...